

- 25
26. (New) The antibody of claim ²³24, wherein said TSG101 protein is human TSG101 protein.
- 26
27. (New) The antibody of claim ²³24, wherein said antibody is detectably labeled.
- 27
28. (New) The antibody of claim ²³24, wherein said antibody is attached to a solid support.
- 28
29. (New) An antibody that binds specifically to a mutated mammalian TSG101 protein.

29
30. (New) The antibody of claim ²⁸29, wherein said mutated TSG101 protein, when present in a mammalian cell, is associated with a transformed phenotype.

- 30
31. (New) The antibody of claim ²⁸29, wherein said antibody is detectably labeled.
- 31
32. (New) The antibody of claim ²⁸29, wherein said antibody is attached to a solid support.
- 32
33. (New) A monoclonal antibody that binds specifically to a coiled coil domain of mammalian TSG101.
- 33
34. (New) The antibody of claim ³²33, wherein said antibody distinguishes between a normal TSG101 protein and a TSG101 protein having a disruption in a coiled coil domain.

- 34
35. (New) The antibody of claim ³²33, wherein said antibody is detectably labeled.
- 35
36. (New) The antibody of claim ³²33, wherein said antibody is attached to a solid support.
- 36
37. (New) A monoclonal antibody that binds specifically to a leucine zipper domain of mammalian TSG101.
- 37
38. (New) The antibody of claim ³⁶37, wherein said antibody distinguishes between a normal TSG101 protein and a TSG101 protein having a disruption in a leucine zipper domain.

1.121 38
39. (New) The antibody of claim ³⁶37, wherein said antibody is detectably labeled.

39
40. (New) The antibody of claim ³⁶37, wherein said antibody is attached to a solid support.

40
41. (New) A monoclonal antibody that binds specifically to a proline rich domain of mammalian TSG101.

41
42. (New) The antibody of claim ⁴⁰41, wherein said antibody distinguishes between a normal TSG101 protein and a TSG101 protein having a disruption in a proline rich domain.

42
43. (New) The antibody of claim ⁴⁰41, wherein said antibody is detectably labeled.

43
44. (New) The antibody of claim ⁴⁰41, wherein said antibody is attached to a solid support.

44
45. (New) A method of diagnosing a tumor, the method comprising contacting a sample comprising a tumor having a mutation in a TSG101 gene with an antibody that distinguishes between normal and abnormal TSG101 protein.

45
46. (New) A method of detecting the presence of an abnormal TSG101 protein in a tumor, comprising contacting a sample from an individual suspected of having a cell with a TSG101 mutation with an antibody that distinguishes between normal and abnormal TSG101, wherein specific binding of the antibody to the sample indicates the presence in the sample of a mutated TSG101 protein.

46
47. (New) The method of claim ⁴⁵46, wherein the mutation is in a coiled coil domain.

47
48. (New) The method of claim ⁴⁵46, wherein the antibody is a monoclonal antibody.

48
49. (New) The method of claim ⁴⁵46, wherein the antibody is detectably labeled.

49
50. (New) The method of claim ⁴⁵46, wherein the antibody is attached to a solid support.